Prescient pauses enrolment for PTX-200 trials to investigate a SAE

Australian-based oncology firm Prescient Therapeutics has temporarily paused enrolment in the clinical trials of its product candidate PTX-200 to further investigate a serious adverse event (SAE) that occurred in one of the trials.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news